Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas - Wikidata - awgldk - TriplyDB

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

http://www.wikidata.org/entity/Q24813451

about

Killing cancer cells by targeted drug-carrying phage nanomedicines Treatment of solid tumors with immunotoxins.In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid Libraries Toxin-based therapeutic approaches Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments.Immunogenicity of therapeutic recombinant immunotoxins.Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins.Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.The future of antiviral immunotoxins.Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.Correction: Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.

P2860

Q21256651-BCA83215-4038-4F77-B8E6-53C2621874EA Q24813585-11CA3217-521F-4455-909E-52762E561733 Q26782129-261084EF-32D1-4F6E-83FE-4D9E598EBAE1 Q27013664-3D76A72B-9490-496A-9EBC-CE7685FE0085 Q27318470-DDC8C5AC-ACA3-4E2F-9E63-0DE16A8E6D59 Q31082210-330EE261-6D11-4140-BECF-7D813D0C5754 Q31115054-0E421501-B5FE-4522-9CD0-87EE1ED39B50 Q33311571-B041F042-5DF3-4CC2-8CE2-5179369580D0 Q33864348-64419857-05FF-4F86-9F4C-F437CE53BF81 Q35538464-9662A888-1585-4B17-9640-C42F5339DEBA Q35837611-C4208FCA-9D6E-4064-8C7D-6C39B8892A14 Q36593468-915C4813-EA7D-4C0B-8A7D-213BE6111262 Q37182201-9DA687F2-1E7B-4606-91DA-4231266568A0 Q37698925-8C3C56C3-1275-40F0-A87A-25CB795148B0 Q37725990-430C16C6-D79D-4EC3-993E-9E3DD16FA1B3 Q38056128-2FD75A1B-F5B9-47F7-98D5-30878D3BD6C4 Q38084826-49646144-99C5-4E67-A84C-5D2468472B06 Q38686601-8AF67900-0503-4D69-943A-493D803CCB4F Q39276348-559F200D-27A6-4412-B48A-BDF584EF2B6B Q39686196-035B0573-3617-4571-A89F-A61087F4D8F9 Q40002915-1D75B54B-7426-45A1-8519-50AEA693A0B7 Q41033340-EE84C1C6-F7D2-407B-B86C-A82944FCBDE5 Q46319719-3D013AD6-DE95-4A72-A04B-8E375ABFB394

P2860

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

http://www.wikidata.org/entity/Q24813451

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase I clinical study of the ...... with advanced solid malignomas

@ast

Phase I clinical study of the ...... with advanced solid malignomas

@en

Phase I clinical study of the ...... with advanced solid malignomas

@nl

type

label

Phase I clinical study of the ...... with advanced solid malignomas

@ast

Phase I clinical study of the ...... with advanced solid malignomas

@en

Phase I clinical study of the ...... with advanced solid malignomas

@nl

prefLabel

Phase I clinical study of the ...... with advanced solid malignomas

@ast

Phase I clinical study of the ...... with advanced solid malignomas

@en

Phase I clinical study of the ...... with advanced solid malignomas

@nl

P1433

Q24813451-F247EF0E-6BC6-4137-9CF2-70B811F1A1D1

P1476

Q24813451-BF7520A7-0DF2-4CE1-868E-832E63FFAC4E

P2093

Q24813451-06D11993-1F26-41D6-A645-3F9BEA85E82A

Q24813451-147C080D-EEF5-42D9-84BB-9F71B0AEBBDD

Q24813451-3333D1A0-C6B1-4D58-B683-ECA78FE275DB

Q24813451-3369E9CC-12E7-40A9-8846-E05D62A791F0

Q24813451-512AFB4B-C1A5-42F3-8114-82B048FA0077

Q24813451-7798BF99-ACE8-495D-A22A-B8D5A1BA2422

Q24813451-7EDD3CFD-2CB4-49C2-A6A8-47A6EFBA01CF

Q24813451-A21B0BDD-1ECC-4738-B5C3-FBC90EB4E9B8

Q24813451-B1C46EED-52AB-4859-9ABE-3FAC1C6B552B

Q24813451-C99EFAFC-6E5E-4B98-9039-E65555D45BBB

P2860

Q24813451-0ADF457D-3222-4987-99BE-B21FEDCDAFFB

Q24813451-0FBC929E-CCA2-45D6-9813-E02A8D7130AC

Q24813451-16517248-9C3F-4D57-9287-A419CC64E49C

Q24813451-182A791B-1A86-4F62-8AA4-B19C36C1AF1F

Q24813451-23DD3F1F-A163-4ECE-A95C-3048559F9C1B

Q24813451-2A4AB879-F60B-4972-90FD-4534415A516C

Q24813451-4355354F-F9FB-44F4-B805-7C31C5A221EB

Q24813451-55A5EA10-E04C-4229-97AB-188BC4049261

Q24813451-6781D14A-6092-4E7A-89B7-850A79E697D7

Q24813451-68862CB4-DDD5-4599-876F-B3D23D61F17C

P2888

Q24813451-8CFC0E7E-101F-4D7E-BFE9-693A66A25002

P304

Q24813451-03A91D6B-5604-475B-A8F0-328FC12F1EE4

P31

Q24813451-BAADF605-A276-4F08-B903-7DA65C012EFD

P356

Q24813451-DE9BD0DD-147F-47D3-BC46-A8F49EFF88D3

P407

Q24813451-C406C716-C3FA-4679-A1F9-9515ABAD6AA3

P433

Q24813451-F21BFB73-3D3D-4F68-8007-CD1953B63F99

P478

Q24813451-EAA54C25-F5B5-4AD4-AF4A-31084F0B89D6

P50

Q24813451-B1693659-BC91-45C6-AD6E-382DB8AD6E84

Q24813451-FFCA5B15-ED06-474D-8A34-7534A6AEE705

P577

Q24813451-7D8EE633-D72E-44CF-A02C-B99CC3F626AA

P5875

Q24813451-06DCF3C5-FD1F-448E-ABE1-F9FB78939C09

P6179

Q24813451-D0438424-58FD-4ADF-8281-403141FE7168

P698

Q24813451-1802527E-B9C7-446B-8E03-EBCFDBF6E736

P921

Q24813451-6B743FAD-BD84-4851-9135-BADF50A4D568

Q24813451-9D44BF19-7064-4BD7-A496-FCBC1DA7149A

P932

Q24813451-0703B4F1-F259-4088-9017-475E30042B07

P356

P1433

Breast Cancer Research

P1476

Phase I clinical study of the ...... with advanced solid malignomas

@en

P2093

Akin Atmaca

http://www.w3.org/2001/XMLSchema#string

Aklil Abera

http://www.w3.org/2001/XMLSchema#string

Alexander B Maurer

http://www.w3.org/2001/XMLSchema#string

Alexander Knuth

http://www.w3.org/2001/XMLSchema#string

Antje Neumann

http://www.w3.org/2001/XMLSchema#string

Christian Cimpoiasu

http://www.w3.org/2001/XMLSchema#string

Dirk Jäger

http://www.w3.org/2001/XMLSchema#string

Elke Jäger

http://www.w3.org/2001/XMLSchema#string

Manfred Kaufmann

http://www.w3.org/2001/XMLSchema#string

Salah-Eddin Al-Batran

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Untangling the ErbB signalling network

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

The ErbB signaling network: receptor heterodimerization in development and cancer

Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

The EGF receptor family as targets for cancer therapy.

Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo.

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines.

P2888

P304

R617-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1264

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Gunter von Minckwitz

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7595829

http://www.w3.org/2001/XMLSchema#string

P6179

1005984431

http://www.w3.org/2001/XMLSchema#string

P698

16168106

http://www.w3.org/2001/XMLSchema#string

P921

P932

1242130

http://www.w3.org/2001/XMLSchema#string